PLN 124.6
(0.48%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 15.38 Million PLN | 66.73% |
2022 | 9.22 Million PLN | 58.1% |
2021 | 5.83 Million PLN | 4689.46% |
2020 | 121.86 Thousand PLN | -58.82% |
2019 | 295.9 Thousand PLN | 159.25% |
2018 | 114.13 Thousand PLN | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 4.45 Million PLN | -9.28% |
2024 Q2 | 3.8 Million PLN | -15.19% |
2023 FY | 15.38 Million PLN | 66.73% |
2023 Q4 | 4.91 Million PLN | 24.36% |
2023 Q1 | 2.49 Million PLN | -25.66% |
2023 Q3 | 3.95 Million PLN | -1.89% |
2023 Q2 | 4.02 Million PLN | 61.64% |
2022 Q3 | 2.66 Million PLN | 48.83% |
2022 Q2 | 1.79 Million PLN | 26.04% |
2022 FY | 9.22 Million PLN | 58.1% |
2022 Q4 | 3.35 Million PLN | 25.79% |
2022 Q1 | 1.42 Million PLN | 5117.79% |
2021 Q4 | -28.31 Thousand PLN | -102.64% |
2021 FY | 5.83 Million PLN | 4689.46% |
2021 Q3 | 1.07 Million PLN | 0.0% |
2020 FY | 121.86 Thousand PLN | -58.82% |
2019 FY | 295.9 Thousand PLN | 159.25% |
2018 FY | 114.13 Thousand PLN | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
BIOTON S.A. | 57.55 Million PLN | 73.271% |
Captor Therapeutics Spolka Akcyjna | 79.91 Million PLN | 80.749% |
Mabion S.A. | 59.52 Million PLN | 74.153% |
Molecure S.A. | 31.73 Million PLN | 51.514% |
NanoGroup S.A. | 7.82 Million PLN | -96.569% |
Pharmena S.A. | -32.76 Million PLN | 146.955% |
Poltreg S.A. | 15.47 Million PLN | 0.583% |
Pure Biologics Spólka Akcyjna | 29.14 Million PLN | 47.211% |
Ryvu Therapeutics S.A. | 4.73 Million PLN | -224.71% |
Synthaverse S.A. | 26.35 Million PLN | 41.623% |
Urteste S.A. | 5.96 Million PLN | -157.788% |